Abstract
Paliperidone palmitate is a long-acting injectable formulation of the atypical antipsychotic paliperidone. The once-monthly injection is approved for acute and maintenance therapy of schizophrenia in adults. Extrapyramidal symptoms are a known adverse effect of antipsychotics; incidence rates of EPS with PP are up to 18%. Given its longer half-life and steady blood levels, PP-induced EPS can cause a sustained and serious functional impairment of several months’ duration, significantly impacting the quality of life.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.